<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T11:30:35Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/215920" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/215920</identifier><datestamp>2025-11-19T10:41:20Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478815</setSpec><setSpec>col_2072_478917</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:Item id="hdl_2445_215920">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:2445/215920</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Proximity-induced pharmacology for amyloid-related diseases&lt;br /></dc:title>
               <dc:creator>Bertran-Mostazo, Andrea</dc:creator>
               <dc:creator>Putriute, Gabrielé</dc:creator>
               <dc:creator>Álvarez-Berbel, Irene</dc:creator>
               <dc:creator>Busquets i Viñas, Ma. Antonia</dc:creator>
               <dc:creator>Galdeano Cantador, Carlos</dc:creator>
               <dc:creator>Espargaró Colomé, Alba</dc:creator>
               <dc:creator>Sabaté Lagunas, Raimon</dc:creator>
               <dc:subject>Malalties neurodegeneratives</dc:subject>
               <dc:subject>Amiloïdosi</dc:subject>
               <dc:subject>Disseny de medicaments</dc:subject>
               <dc:subject>Neurodegenerative Diseases</dc:subject>
               <dc:subject>Amyloidosis</dc:subject>
               <dc:subject>Drug design</dc:subject>
               <dc:description>&lt;p>Proximity-induced pharmacology (PIP) for amyloid-related diseases is a cutting-edge&lt;/p>&lt;p>approach to treating conditions such as Alzheimer’s disease and other forms of dementia. By bringing&lt;/p>&lt;p>small molecules close to amyloid-related proteins, these molecules can induce a plethora of effects&lt;/p>&lt;p>that can break down pathogenic proteins and reduce the buildup of plaques. One of the most&lt;/p>&lt;p>promising aspects of this drug discovery modality is that it can be used to target specific types of&lt;/p>&lt;p>amyloid proteins, such as the beta-amyloid protein that is commonly associated with Alzheimer’s&lt;/p>&lt;p>disease. This level of specificity could allow for more targeted and effective treatments. With ongoing&lt;/p>&lt;p>research and development, it is hoped that these treatments can be refined and optimized to provide&lt;/p>&lt;p>even greater benefits to patients. As our understanding of the underlying mechanisms of these&lt;/p>&lt;p>diseases continues to grow, proximity-induced pharmacology treatments may become an increasingly&lt;/p>&lt;p>important tool in the fight against dementia and other related conditions.&lt;/p></dc:description>
               <dc:date>2024-10-21T10:49:16Z</dc:date>
               <dc:date>2024-10-21T10:49:16Z</dc:date>
               <dc:date>2024-03-04</dc:date>
               <dc:date>2024-10-21T10:49:16Z</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:relation>Reproducció del document publicat a: https://doi.org/10.3390/cells13050449</dc:relation>
               <dc:relation>Cells, 2024, vol. 13</dc:relation>
               <dc:relation>https://doi.org/10.3390/cells13050449</dc:relation>
               <dc:rights>cc-by (c)  Bertran-Mostazo, A. et al., 2024</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>MDPI</dc:publisher>
               <dc:source>Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>